CytomX Therapeutics, Inc. (CTMX) Stake Raised by Algert Global LLC

Algert Global LLC raised its holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 31.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 45,853 shares of the biotechnology company’s stock after buying an additional 11,050 shares during the quarter. Algert Global LLC owned about 0.12% of CytomX Therapeutics worth $833,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of CTMX. Legal & General Group Plc grew its position in shares of CytomX Therapeutics by 28.6% in the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock worth $101,000 after buying an additional 1,434 shares during the last quarter. Macquarie Group Ltd. bought a new stake in shares of CytomX Therapeutics in the 3rd quarter worth approximately $107,000. Cubist Systematic Strategies LLC bought a new stake in shares of CytomX Therapeutics in the 2nd quarter worth approximately $174,000. Goldman Sachs Group Inc. purchased a new position in shares of CytomX Therapeutics in the 1st quarter valued at approximately $190,000. Finally, Voya Investment Management LLC purchased a new position in shares of CytomX Therapeutics in the 2nd quarter valued at approximately $203,000. Hedge funds and other institutional investors own 63.18% of the company’s stock.

A number of research analysts have recently commented on the company. BidaskClub upgraded CytomX Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday. Wedbush assumed coverage on CytomX Therapeutics in a research note on Thursday, September 7th. They issued an “outperform” rating and a $26.00 target price for the company. Cowen restated an “outperform” rating on shares of CytomX Therapeutics in a research note on Thursday, October 5th. Jefferies Group set a $25.00 target price on CytomX Therapeutics and gave the company a “buy” rating in a research note on Friday, August 25th. Finally, ValuEngine cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $31.88.

In other CytomX Therapeutics news, insider Sean A. Mccarthy sold 14,340 shares of CytomX Therapeutics stock in a transaction on Friday, December 1st. The stock was sold at an average price of $20.60, for a total transaction of $295,404.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Sean A. Mccarthy sold 19,120 shares of CytomX Therapeutics stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $24.13, for a total value of $461,365.60. Following the transaction, the chief executive officer now owns 23,365 shares of the company’s stock, valued at approximately $563,797.45. The disclosure for this sale can be found here. Insiders have sold 173,009 shares of company stock valued at $3,835,417 in the last quarter. 4.70% of the stock is owned by company insiders.

CytomX Therapeutics, Inc. (NASDAQ CTMX) opened at $21.57 on Monday. CytomX Therapeutics, Inc. has a one year low of $10.40 and a one year high of $24.67.

COPYRIGHT VIOLATION WARNING: This piece was published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://sportsperspectives.com/2017/12/18/cytomx-therapeutics-inc-ctmx-stake-raised-by-algert-global-llc.html.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply